Literature DB >> 7912987

Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.

P Birrer1, N G McElvaney, A Rüdeberg, C W Sommer, S Liechti-Gallati, R Kraemer, R Hubbard, R G Crystal.   

Abstract

Cystic fibrosis (CF) is characterized in the lung by chronic purulent bronchitis culminating in pulmonary insufficiency. There is evidence to suggest that neutrophil elastase (NE) released by neutrophils on the respiratory epithelial surface plays a major role in the pathogenesis of this lung disease. This study sought to determine the age of onset of the chronic neutrophil-dominated inflammation in CF and the consequences to the NE-anti-NE screen on the respiratory epithelial surface of the CF lung. NE and anti-NE defensive molecules were evaluated in respiratory epithelial lining fluid (ELF) in 27 children with stable CF (1 to 18 yr of age). Despite normal antigenic concentrations of alpha 1-antitrypsin (alpha 1AT) and secretory leukoprotease inhibitor (SLPI), 25 of 27 children with CF had neutrophil-dominated inflammation (> 500 neutrophils/microliters ELF). Active NE was found in ELF in 20 of 27 children, including two of four aged 1 yr. Western blot analysis showed the majority of alpha 1AT and SLPI molecules to be complexed and/or degraded. These observations demonstrate that a chronic imbalance of the NE-anti-NE protective screen develops early on the respiratory epithelial surface in persons with CF and is likely well established by 1 yr of age, with resultant potential for lung damage.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912987     DOI: 10.1164/ajrccm.150.1.7912987

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  88 in total

Review 1.  New therapeutic approaches for cystic fibrosis lung disease.

Authors:  Jane C Davies
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition.

Authors:  J Cooley; M K Sontag; F J Accurso; E Remold-O'Donnell
Journal:  Eur Respir J       Date:  2010-09-03       Impact factor: 16.671

3.  Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study.

Authors:  V Thompson; N Mayer-Hamblett; M Kloster; D Bilton; P A Flume
Journal:  J Cyst Fibros       Date:  2015-02-25       Impact factor: 5.482

4.  Global genomic analysis of AlgU (sigma(E))-dependent promoters (sigmulon) in Pseudomonas aeruginosa and implications for inflammatory processes in cystic fibrosis.

Authors:  Aaron M Firoved; J Cliff Boucher; Vojo Deretic
Journal:  J Bacteriol       Date:  2002-02       Impact factor: 3.490

Review 5.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 6.  Role of corticosteroids in cystic fibrosis lung disease.

Authors:  I M Balfour-Lynn; R Dinwiddie
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

Review 7.  Use of modulators of airways inflammation in patients with CF.

Authors:  Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  CFTR and differentiation markers expression in non-CF and delta F 508 homozygous CF nasal epithelium.

Authors:  F Dupuit; N Kälin; S Brézillon; J Hinnrasky; B Tümmler; E Puchelle
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

9.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

10.  Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Authors:  Scott D Sagel; Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Jeffrey S Wagener; Bonnie W Ramsey
Journal:  J Pediatr       Date:  2008-09-25       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.